Every major bio/pharmaceutical development journey today either begins in or makes its way to Europe. If you view Europe as a single entity encompassing the European Union (EU) and states lying just beyond the borders of the EU, it is the second-largest bio/pharmaceuticals market on earth, after North America. Europe is also home to many of the world’s top university-based pharmaceuticals and biotech research laboratories, as well as several of the largest international bio/pharmaceuticals companies.
PAREXEL is proud to be a part of that fully-integrated development infrastructure, with 38 offices and research facilities in 20 different countries across Europe, stretching from the United Kingdom to Turkey and from Finland to Spain. This gives us ready access to superior talent, patient populations, and clinical trial facilities, while also allowing us to operate in close proximity to many of those client companies that choose us as their development partner.
PAREXEL’s European operations provide you with end-to-end clinical research services through every phase, integrated eClinical technologies, and results-driven commercialization services worldwide. Additionally, PAREXEL has in-depth regulatory knowledge and resources that can accelerate your development journey to and through the EMA, the National Health Authorities, and local Health Technology Agencies (HTAs) that are gateways to product regulatory approval and reimbursement, even as we reduce your costs and overhead. Click each location for contact details.